Comment: Paediatric rhabdomyosarcoma survival extended with maintenance chemotherapy

Bookmark and Share
Published: 3 Jun 2018
Views: 1326
Prof Richard Schilsky & Dr Gianni Bisogno

Prof Richard Schilsky and Dr Gianni Bisogno comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.

For more detail, watch Dr Bisogno present the data in the press conference, watch Dr Bisogno speak with ecancer about the trial here, or read our news coverage here.